核苷(酸)类似物抗病毒治疗慢性乙型肝炎患者发生原发性肝癌的危险因素分析

肝脏 ›› 2018, Vol. 23 ›› Issue (10): 864-867.

核苷(酸)类似物抗病毒治疗慢性乙型肝炎患者发生原发性肝癌的危险因素分析

蒋蒙, 刘亚允, 孙双双, 陈尚军, 梁雪松

200433 上海海军医科大学附属长海医院感染科(蒋蒙,刘亚允,孙双双,梁雪松);解放军第四一三医院感染科(陈尚军)

收稿日期:2018-07-20 出版日期:2018-10-31 发布日期:2020-05-21
通讯作者: 梁雪松,Email:liangxuesong2000@163.com

Risk factors for hepatocellular carcinoma among patients with chronic hepatitis B in the era of nucleos(t)ide analogues treatment

JIANG Meng, LIU Ya-yun, SUN Shuang-shuang, CHEN Shang-jun, LIANG Xue-song.

Department of Infectious Diseases, Changhai Hospital, Shanghai 200433, China;
Department of Infectious Diseases, 413 Military Hospital, Zhoushan 316000, China

Received:2018-07-20 Online:2018-10-31 Published:2020-05-21
Contact: LIANG Xue-song, Email: liangxuesong2000@163.com

摘要/Abstract

摘要： 目的分析抗病毒治疗慢性乙型肝炎(CHB)患者发生原发性肝癌(HCC)的危险因素。方法采用问卷调查法采集2013年3月至2017年9月在解放军第四一三医院感染科就诊的285例CHB患者临床转归及相关因素等资料,行单因素及多因素分析以评估CHB患者发生HCC的危险因素。结果单因素分析显示,男性、年龄>40岁、未抗病毒治疗、肝硬化程度、高HBV DNA水平、有HCC家族史在CHB患者HCC发生方面差异有统计学意义(P<0.05);将上述因素纳入多因素Logistic回归分析显示,年龄>40岁(OR=3.318,P=0.019)、未抗病毒治疗(OR=2.709,P=0.002)、有HCC家族史(OR=2.096,P=0.037)、肝硬化程度为CHB患者发生HCC的主要危险因素。肝硬化患者中Child-Pugh C级、Child-Pugh B级、Child-Pugh A级与无肝硬化相比,HCC发生风险均显著升高(OR值分别为18.453、13.395、6.970,P=0.000)。结论年龄>40岁、肝硬化程度、未抗病毒治疗和有HCC家族史是发生HCC的主要危险因素,对于具有上述危险因素的人群应及时启动抗病毒治疗并加强随访工作。

关键词: 慢性乙型肝炎;原发性肝癌;核苷(酸)类似物;危险因素

Abstract: Objective To analyze risk factors for hepatocellular carcinoma (HCC) among patients with chronic hepatitis B (CHB) in the era of continuous treatment with nucleos(t)ide analogues. OMethods In this study, questionnaire survey was used to collect the clinical data of 285 patients with CHB enrolled in Department of Infectious Diseases in 413 Military Hospital from March 2013 to September 2017. Risk factors for HCC were identified by univariate and multivariate analysis. Results Univariate analysis showed that gender, age, antiviral treatment, cirrhosis statue, serum hepatitis B virus (HBV) DNA level, and HCC family history were correlated with development of HCC among patients with CHB (P<0.05). Furthermore, multivariate logistic regression analysis showed that age older than 40 years (OR=3.318, P=0.019), no antiviral therapy (OR=2.709,P=0.002), HCC family history (OR=2.096,P=0.037), and cirrhosis were the main risk factors for HCC development. Child-Pugh C, B and A patients with cirrhosis all had significantly higher risk of HCC than those without cirrhosis (OR-C=18.453,OR-B=13.395,OR-A=6.970,P=0.000).Conclusion Age older than 40 years, cirrhosis statue, no antiviral treatment, family history of HCC are major risk factors for HCC development. Patients with risk factors should receive prompt antiviral treatment and be closely followed up.

Key words: Chronic Hepatitis B; Hepatocellular carcinoma; Nucleos(t)ide analogues; Risk factors

蒋蒙, 刘亚允, 孙双双, 陈尚军, 梁雪松. 核苷(酸)类似物抗病毒治疗慢性乙型肝炎患者发生原发性肝癌的危险因素分析[J]. 肝脏, 2018, 23(10): 864-867.

JIANG Meng, LIU Ya-yun, SUN Shuang-shuang, CHEN Shang-jun, LIANG Xue-song.. Risk factors for hepatocellular carcinoma among patients with chronic hepatitis B in the era of nucleos(t)ide analogues treatment[J]. Chinese Hepatolgy, 2018, 23(10): 864-867.

参考文献

[1] Liaw YF, Leung N, Kao JH, et al. Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int, 2008,2:263-283.
[2] El-Serag HB. Hepatocellular carcinoma. N Engl J Med, 2011,365:1118-1127.
[3] Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 2004,351:1521-1531.
[4] Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology, 2013,57:399-408.
[5] Niro GA, Ippolito AM, Fontana R, et al. Long-term outcome of hepatitis B virus-related chronic hepatitis under protracted nucleos(t)ide analogues. J Viral Hepatol,2013,20:502-507.
[6] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版).中华肝脏病杂志,2011,19:13-24.
[7] 王洪,王英民,张波.乙肝肝硬化患者并发肝癌的危险因素研究.临床肝胆病杂志,2007,23:34-35.
[8] Ljumovic D, Diamantis I, Alegakis AK, et al. Diferential expression of matrix metalloproteinase in viral and non-viral chronic liver diseases.Chin Chim Acta,2004,349:203-211.
[9] Tsai MC, Chen CH, Hu TH, et al. Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. J Formos Med, 2017,116:512-521.
[10] 许明妍,兰英华,李用国. 核苷(酸)类似物抗病毒治疗对乙型肝炎相关性肝癌发生的影响.中华肝脏病杂志,2014,22:312-314.
[11] 黄玉波,乔雍,常路丝,等.抗病毒治疗对失代偿期乙肝肝硬化患者预后的影响.胃肠病学和肝病学杂志,2011,20:331-333.
[12] 张玲霞,周先志.现代传染病学.2版.人民军医出版社,2010:397-398.
[13] 孙燕,屠红,陆培新,等.肝癌家族史与肝癌关系的20年前瞻性队列研究.中华肝脏病杂志,2014,22:752-756.
[14] Park CH, Jeong SH, Yim HW, et al.Family history influences the early onset of hepatocellular carcinoma. World J Gastroenterol, 2012,18:2661-2667.
[15] 巫贵成,周卫平,赵有蓉,等.乙型肝炎e抗原阴性和阳性慢性乙型肝炎患者临床转归的回顾性分析.中华传染病杂志,2007,25:166-168.
[16] Hsu YC, Yip TC, Ho HJ, et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. Hepatol,2018,69:278-285.